Spiriva®
Tiotropium is a long-acting muscarinic antagonist (LAMA) for maintenance treatment of COPD and asthma. Provides 24-hour bronchodilation.
| Dosage Form | Inhaler (DPI HandiHaler / Soft Mist Respimat) |
| Strength | 18 mcg capsule (DPI); 1.25 mcg, 2.5 mcg per actuation (Respimat) |
| Storage | Store at 25°C. Do not expose capsules to extreme temperatures/moisture. |
| Category | Respiratory |
| Availability | Available for Transfer |
COPD (maintenance to reduce exacerbations); asthma (add-on maintenance, ≥6 years).
Quaternary ammonium compound that selectively blocks M3 muscarinic receptors in airway smooth muscle. Dissociates very slowly from M3 receptors, providing prolonged bronchodilation.
Each Burrard Pharmaceuticals technology transfer package for Tiotropium includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.